Precision medicine is refocusing which clinical trials are possible, but we still have a ~5% participation rate and non-diverse patient demographic. Community oncology is the doorway to changing the face of clinical trials in the era of precision medicine. In this podcast, we talk about why, how and what’s in it for your practice to facilitate clinical trials in the community setting.
Learn more about our partners at VieCure.
Dr. Paul Bunn Jr., MD, FASCO: Dr. Bunn is a Distinguished Professor, VieCure Clinical Advisory Council Member, and James Dudley Endowed Chair in Lung Cancer Research Division of Medical Oncology University of Colorado.
Dr. Fred Ashbury, PhD, MACE: Dr. Ashbury is a co-founder and Chief Scientific Officer at VieCure. He is responsible for developing and maintaining VieCure’s oncology clinical content, genomic-science knowledge identification and codification, and the design and implementation of the treatment strategy rules that underpin our platform.
The content and information contained in this podcast is provided [exclusively or solely] by VieCure and AmerisourceBergen is not responsible and does not verify for accuracy any of the information contained in the podcast. The primary purpose of the podcast is to educate and inform. This podcast does not constitute medical or other professional advice or services.